Need to keep on prime of the science and politics driving biotech in the present day? Join to get our biotech publication in your inbox.
Though RevMed’s experimental pancreatic most cancers drug, daraxonrasib, hasn’t but achieved approval, it’s obtainable by means of an expanded entry program. However that doesn’t imply getting it’s straightforward.
Additionally, the FDA’s voucher program spearheaded by erstwhile chief Marty Makary may very well be in for a makeover.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
View All Plans
